The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imaging methodology at the molecular, cellular and biosystem level. This is accomplished by facilitating development of novel basic science and clinical research, promoting advances in biotechnology, fostering development of new Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offers customized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancer detection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v) pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescence imaging of live animals and facilitates collaborative microPET research in conjunction with the University at Buffalo (UB).
The aim i s to provide readily available access and training to noninvasive, state-of-the-art in vivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7 days/week. Three general types of MR services are offered: (a) instrumentation and expertise to acquire high resolution (<50 urn2 in-plane spatial and <100 ms temporal) heteronuclear imaging and spectroscopy data, (b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets for probing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnet incorporating Bruker's Avance platform with ParaVision? 4.0 OS, shielded Accustar gradients and digital system electronics. The MR system represents the highest magnetic field strength scanner available within 200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectral fluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also available for fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitative analysis and 3D renderings of digitally acquired data sets are offered as chargeback services. The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSG support is requested, representing 12% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-36W2
Application #
8724583
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-05-01
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
36
Fiscal Year
2013
Total Cost
$33,330
Indirect Cost
$13,701
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Wintrob, Zachary A P; Hammel, Jeffrey P; Nimako, George K et al. (2017) Insulin use, hormone receptor status and hematopoietic cytokines? circulation in women with diabetes mellitus and breast cancer. Data Brief 11:382-390
Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5
Liu, Song; Kumari, Sangeeta; Hu, Qiang et al. (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:
Espinal, Allyson C; Buas, Matthew F; Wang, Dan et al. (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166:559-568
Danaher, Patrick; Warren, Sarah; Dennis, Lucas et al. (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18
Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608
Gage-Bouchard, Elizabeth A (2017) Social support, flexible resources, and health care navigation. Soc Sci Med 190:111-118
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Ho, Christine M; McCarthy, Philip L; Wallace, Paul K et al. (2017) Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv 1:1056-1066

Showing the most recent 10 out of 1391 publications